- Home
- CYRX vs PGEN Comparison
CYRX vs PGEN Comparison
Compare CYRX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | PGEN |
|---|---|---|
| Founded | 1999 | 1998 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.3M | 1.6B |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CYRX | PGEN |
|---|---|---|
| Price | $15.52 | $5.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $13.31 | $8.33 |
| AVG Volume (30 Days) | 818.9K | ★ 5.5M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $176,177,000.00 | ★ $230,981,000.00 |
| Revenue This Year | $11.06 | $1,115.92 |
| Revenue Next Year | $8.45 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.69 | $1.47 |
| 52 Week High | $16.73 | $6.04 |
Technical Indicators
Market Signals| Indicator | CYRX | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 64.35 |
| Support Level | $14.29 | $3.32 |
| Resistance Level | $16.73 | N/A |
| Average True Range (ATR) | 0.66 | 0.34 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 50.64 | 75.46 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.